A schematic representation of the putative effect of sodium/glucose co-transporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonist (GLP-1RAs) on multiple cardiovascular risk factors in type 2 diabetes mellitus (T2DM). Each of these two classes target multiple phenomena possibly explaining the observed beneficial cardiovascular effect. Red lines: consistent, likely relevant effect; yellow lines: weak effect, unlikely to be responsible for the observed cardiovascular outcome; white: neutral effect; light blue: few data available in clinical settings. The intensity of the effect is postulated by the authors based on available clinical data and current literature.